Skip to main content
SpringerLink
Log in

Epidemiology of Diffuse Low Grade Gliomas

  • Chapter
  • First Online:
Diffuse Low-Grade Gliomas in Adults

Abstract

Diffuse low grade gliomas (DLGGs) belong to primary central nervous system tumors (PCNSTs) and include diffuse astrocytomas (fibrillary/gemistocytic/protoplasmic astrocytomas), oligodendroglioma and oligoastrocytoma, according to the previous WHO classification. Here, we present the 2016 WHO Classification, but epidemiological data are available only for the previous one. Although specific epidemiological publications focusing on DLGG are very rare, it is nonetheless possible to collect information concerning DLGG by selecting data from the whole epidemiological literature on gliomas. The present work summarizes definitions and descriptive epidemiological data for DLGG and PCNST. DLGGs account for approximately 15% of all gliomas, and incidence rate is about 1/100,000 person-years. Main prognostic factors (e.g., age, performance status, location, volume and growth rate of the tumor, extent of surgical resection, histology, biology, etc.) are discussed and it is shown how they influence survival. Recent literature proposes a lot of spontaneous prognostic factors, but until now, just a few are validated. On the other hand, little data are available to define best combinations of the different therapeutic strategies at the individual level (successive surgeries, chemotherapy, radiotherapy and new treatments). This chapter proposes new efficient methodology to evaluate medical care and quality of life taking into account the specific property of the brain, i.e. neuroplasticity. The developments of modern informatics technology will revolutionize our methods of recording data. Collaboration between all medical specialties (including epidemiology and biostatistics) and development of large databases are the key of efficiency for the future. This chapter also summarizes the knowledge about DLGG risk factors and proposes new directions for searching etiologies of these tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO classification of tumours of the central nervous system. Lyon, France: International Agency for Research on Cancer; 2007.

    Google Scholar 

  2. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–20.

    Article  PubMed  Google Scholar 

  3. Arora RS, Alston RD, Eden TOB, Estlin EJ, Moran A, Geraci M, et al. Are reported increases in incidence of primary CNS tumours real? An analysis of longitudinal trends in England, 1979–2003. Eur J Cancer. 2010;46:1607–16.

    Article  PubMed  Google Scholar 

  4. Bondy ML, Scheurer ME, Malmer B, Barnholtz-Sloan JS, Davis FG, Il’yasova D, et al. Brain tumor epidemiology: consensus from the brain tumor epidemiology consortium. Cancer. 2008;113(Suppl.7):1953–68.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Kleihues P, Cavenee WK. World health classification of tumors. Tumours of the nervous system: pathology and genetics. Lyon, France: International Agency for Research on Cancer; 2000.

    Google Scholar 

  6. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109.

    Article  PubMed  PubMed Central  Google Scholar 

  7. McCarthy BJ, Surawicz T, Bruner JM, Kruchko C, Davis F. Consensus conference on brain tumor definition for registration. Neuro-Oncol. 2002;4:134–45.

    Article  PubMed  PubMed Central  Google Scholar 

  8. McCarthy BJ, Kruchko C. Central brain tumor registry of United States. Consensus conference on cancer registration of brain and central nervous system tumors. Neuro-Oncol. 2005;7:196–201.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Wrensch M, Minn Y, Chew T, Bondy M, Berger MS. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro-Oncol. 2002;4:278–99.

    PubMed  PubMed Central  Google Scholar 

  10. Kohler BA, Ward E, McCarthy BJ, Schymura MJ, Ries LA, Eheman C, et al. Annual report to the nation on the status of cancer, 1975–2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst. 2011;103:714–36.

    Article  PubMed  PubMed Central  Google Scholar 

  11. DeAngelis LM. Brain tumors. N Engl J Med. 2001;344:114–23.

    Article  CAS  PubMed  Google Scholar 

  12. Bauchet L, Rigau V, Mathieu-Daudé H, Figarella-Branger D, Hugues D, Palusseau L, et al. French brain tumor data bank: methodology and first results on 10,000 cases. J Neuro-Oncol. 2007;84:189–99.

    Article  Google Scholar 

  13. Bauchet L, Rigau V, Mathieu-Daudé H, Fabbro-Peray P, Palenzuela G, Figarella-Branger D, et al. Clinical epidemiology for childhood primary central nervous system tumors. J Neuro-Oncol. 2009;92:87–98.

    Article  Google Scholar 

  14. Wöhrer A, Waldhör T, Heinzl H, Hackl M, Feichtinger J, Gruber-Mösenbacher U, et al. The Austrian brain tumour registry: a cooperative way to establish a population-based brain tumour registry. J Neuro-Oncol. 2009;95:401–11.

    Article  Google Scholar 

  15. CBTRUS. CBTRUS 2009–2010 eighteen states statistical report tables. Published by the Central Brain Tumor Registry of the United States, Hinsdale, IL, 2009.

    Google Scholar 

  16. CBTRUS. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004–2007. Published by the Central Brain Tumor Registry of the United States, Hinsdale, IL, 2011.

    Google Scholar 

  17. CBTRUS 2012: Central Brain Tumor Registry of the United States, Statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004–2008. http://www.cbtrus.org/2012-NPCR-SEER/CBTRUS_Report_2004-2008_3-23-2012.pdf. Accessed 30 July 2016.

  18. Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro-Oncol. 2015;17(Suppl 4):iv1–iv62.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Rigau V, Zouaoui S, Mathieu-Daudé H, Darlix A, Maran A, Trétarre B, et al. French brain tumor database: 5-year histological results on 25,756 cases. Brain Pathol. 2011;21:633–44.

    Article  PubMed  Google Scholar 

  20. Baldi I, Gruber A, Alioum A, Berteaud E, Lebailly P, Huchet A, et al. Descriptive epidemiology of CNS tumors in France: results from the gironde registry for the period 2000–2007. Neuro-Oncol. 2011;13:1370–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. ENCR, European Network of Cancer Registries. Recommendations for coding tumours of the brain and central nervous system. Available at: http://www.ror-sul.org.pt/media/1057/recommendations-for-coding-tumours-of-the-brain-and-central-nervous-system.pdf. Distributed in 1998. Accessed 17 August 2016.

  22. Zouaoui S, Rigau V, Mathieu-Daudé H, Darlix A, Bessaoud F, Fabbro-Peray P, et al. French brain tumor database: general results on 40,000 cases, main current applications and future prospects. Neurochirurgie. 2012;58:4–13.

    Article  CAS  PubMed  Google Scholar 

  23. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al. International classification of diseases for oncology. Third ed. Geneva: World Health Organization; 2000.

    Google Scholar 

  24. Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, et al. Cancer incidence in five continents vol. X. Lyon, France: IARC; 2014.

    Google Scholar 

  25. Hartmann C, Mueller W, von Deimling A. Pathology and molecular genetics of oligodendroglial tumors. J Mol Med. 2004;82:638–55.

    Article  CAS  PubMed  Google Scholar 

  26. McCarthy BJ, Propp JM, Davis FG, Burger PC. Time trends in oligodendroglial and astrocytic tumor incidence. Neuroepidemiology. 2008;30:34–44.

    Article  PubMed  Google Scholar 

  27. Daumas-Duport C, Beuvon F, Varlet P, Fallet-Bianco C. Gliomas: WHO and Sainte-Anne hospital classifications. Ann Pathol. 2000;20:413–28.

    CAS  PubMed  Google Scholar 

  28. Mittler MA, Walters BC, Stopa EG. Observer reliability in histological grading of astrocytoma stereotactic biopsies. J Neurosurg. 1996;85:1091–4.

    Article  CAS  PubMed  Google Scholar 

  29. Capelle L, Fontaine D, Mandonnet E, Taillandier L, Golmard JL, Bauchet L, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization grade II gliomas: a series of 1097 cases: clinical article. J Neurosurg. 2013;118:1157–68.

    Article  PubMed  Google Scholar 

  30. Ruiz J, Lesser GJ. Low-grade gliomas. Curr Treat Options Oncol. 2009;10:231–42.

    Article  PubMed  Google Scholar 

  31. Bristol RE. Low-grade glial tumors: are they all the same? Semin Pediatr Neurol. 2009;16:23–6.

    Article  PubMed  Google Scholar 

  32. Piepmeier JM. Current concepts in the evaluation and management of WHO grade II gliomas. J Neuro-Oncol. 2009;92:253–9.

    Article  Google Scholar 

  33. Darlix A, Zouaoui S, Virion JM, Rigau V, Mathieu-Daudé H, Blonski M, et al. Significant heterogeneity in the geographical distribution of diffuse grade II/III gliomas in France. J Neuro-Oncol. 2014;120:547–55.

    Article  Google Scholar 

  34. Zouaoui S, Darlix A, Rigau V, Mathieu-Daudé H, Bauchet F, Bessaoud F, et al. Descriptive epidemiology of 13,038 newly diagnosed and histologically confirmed meningiomas in France: 2006–2010. Neurochirurgie. 2015 Jun 11. [Epub ahead of print].

    Google Scholar 

  35. Bauchet L, Rigau V, Zouaoui S, Darlix A, Bessaoud F, Bauchet F, et al. French national histological brain tumor registry. J Clin Oncol. 2015;33. (suppl; abstr e13051).

    Google Scholar 

  36. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005;109:93–108.

    Article  PubMed  Google Scholar 

  37. Okamoto Y, Di Patre PL, Burkhard C, Horstmann S, Jourde B, Fahey M, et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol. 2004;108:49–56.

    Article  PubMed  Google Scholar 

  38. Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, et al. The epidemiology of glioma in adults: a “state of the science review”. Neuro-Oncol. 2014;16(7):896–913.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Pedeutour-Braccini Z, Burel-Vandenbos F, Gozé C, Roger C, Bazin A, Costes-Martineau V, et al. Microfoci of malignant progression in diffuse low-grade gliomas: towards the creation of an intermediate grade in glioma classification? Virchows Arch. 2015;466:433–44.

    Article  CAS  PubMed  Google Scholar 

  40. Katzman GL, Dagher AP, Patronas NJ. Incidental findings on brain magnetic resonance imaging from 1000 asymptomatic volunteers. JAMA. 1999;282(1):36–9.

    Article  CAS  PubMed  Google Scholar 

  41. Morris Z, Whiteley WN, Longstreth Jr WT, Weber F, Lee YC, Tsushima Y, et al. Incidental findings on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2009;339. b3016.

    Google Scholar 

  42. Bos D, Poels MM, Adams HH, Akoudad S, Cremers LG, Zonneveld HI, et al. Prevalence, clinical management, and natural course of incidental findings on brain MR images: the population-based rotterdam scan study. Radiology. 2016;23:160218. [Epub ahead of print].

    Google Scholar 

  43. Kelly PJ. Gliomas: survival, origin and early detection. Surg Neurol Int. 2010;1:96.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Lima GL, Zanello M, Mandonnet E, Taillandier L, Pallud J, Duffau H. Incidental diffuse low-grade gliomas: from early detection to preventive neuro-oncological surgery. Neurosurg Rev. 2016;39:377–84.

    Article  PubMed  Google Scholar 

  45. Mandonnet E, de Witt HP, Duffau H. MRI screening for glioma: a preliminary survey of healthy potential candidates. Acta Neurochir. 2016;158:905–6.

    Article  PubMed  Google Scholar 

  46. Nielsen MS, Christensen HC, Kosteljanetz M, Johansen C. Incidence of and survival from oligodendroglioma in Denmark, 1943–2002. Neuro-Oncol. 2009;11:311–7.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Sant M, Minicozzi P, Lagorio S, Børge Johannesen T, Marcos-Gragera R, Francisci S, et al. Survival of European patients with central nervous system tumors. Int J Cancer. 2012;131:173–85.

    Article  CAS  PubMed  Google Scholar 

  48. Visser O, Ardanaz E, Botta L, Sant M, Tavilla A, Minicozzi P, EUROCARE-5 Working Group. Survival of adults with primary malignant brain tumours in Europe; results of the EUROCARE-5 study. Eur J Cancer. 2015;5. [Epub ahead of print].

    Google Scholar 

  49. Crocetti E, Trama A, Stiller C, Caldarella A, Soffietti R, Jaal J, et al. Epidemiology of glial and non-glial brain tumours in Europe. Eur J Cancer. 2012;48:1532–42.

    Article  PubMed  Google Scholar 

  50. Tseng MY, Tseng JH, Merchant E. Comparison of effects of socioeconomic and geographic variations on survival for adults and children with glioma. J Neurosurg. 2006;105(Suppl 4):297–305.

    PubMed  Google Scholar 

  51. Jung KW, Yoo H, Kong HJ, et al. Population-based survival data for brain tumors in Korea. J Neuro-Oncol. 2012;109:301–7.

    Article  Google Scholar 

  52. Ho VK, Reijneveld JC, Enting RH, Bienfait HP, Robe P, Baumert BG, et al. Changing incidence and improved survival of gliomas. Eur J Cancer. 2014;50:2309–18.

    Article  PubMed  Google Scholar 

  53. Asklund T, Malmström A, Bergqvist M, Björ O, Henriksson R. Brain tumors in Sweden: data from a population-based registry 1999–2012. Acta Oncol. 2015;54:377–84.

    Article  PubMed  Google Scholar 

  54. Claus EB, Black PM. Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the SEER program, 1973–2001. Cancer. 2006;106:1358–63.

    Article  PubMed  Google Scholar 

  55. Claus EB, Walsh KM, Wiencke JK, Molinaro AM, Wiemels JL, Schildkraut JM, et al. Survival and low-grade glioma: the emergence of genetic information. Neurosurg Focus. 2015;38(1):E6.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Davis FG, Kupelian V, Freels S, McCarthy B, Surawicz T. Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. Neuro-Oncol. 2001;3:152–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  57. Porter KR, McCarthy BJ, Freels S, Kim Y, Davis FG. Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Neuro-Oncol. 2010;12:520–7.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Mandonnet E, de Witt HP, Pallud J, Bauchet L, Whittle I, Duffau H. Silent diffuse low-grade glioma: toward screening and preventive treatment? Cancer. 2014;120:1758–62.

    Article  PubMed  Google Scholar 

  59. Cook MB, Dawsey SM, Freedman ND, Inskip PD, Wichner SM, Quraishi SM, et al. Sex disparities in cancer incidence by period and age. Cancer Epidemiol Biomark Prev. 2009;18:1174–82.

    Article  Google Scholar 

  60. Soffietti R, Baumert BG, Bello L, von Deimling A, Duffau H, Frénay M, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO task force. Eur J Neurol. 2010;17:1124–33.

    Article  CAS  PubMed  Google Scholar 

  61. Sanai N, Chang S, Berger MS. Low-grade gliomas in adults. J Neurosurg. 2011;115:948–65.

    Article  PubMed  Google Scholar 

  62. Loiseau H, Bousquet P, Rivel J, Vital C, Kantor G, Rougier A, et al. Supra-tentorial low-grade astrocytomas in adults. Prognostic factors and therapeutic indications. Apropos of a series of 141 patients. Neurochirurgie. 1995;41:38–50.

    CAS  PubMed  Google Scholar 

  63. Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002;20:2076–84.

    Article  PubMed  Google Scholar 

  64. van Veelen ML, Avezaat CJ, Kros JM, van Putten W, Vecht C. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery. J Neurol Neurosurg Psychiatry. 1998;64:581–7.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Pallud J, Audureau E, Blonski M, Sanai N, Bauchet L, Fontaine D, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain. 2014;137:449–62.

    Article  PubMed  Google Scholar 

  66. Berger MS, Rostomily RC. Low grade gliomas: functional mapping resection strategies, extent of resection, and outcome. J Neuro-Oncol. 1997;34:85–101.

    Article  CAS  Google Scholar 

  67. Duffau H, Capelle L. Preferential brain locations of low-grade gliomas. Cancer. 2004;100:2622–6.

    Article  PubMed  Google Scholar 

  68. Parisot S, Darlix A, Baumann C, Zouaoui S, Yordanova Y, Blonski M, et al. A probabilistic atlas of diffuse WHO grade II glioma locations in the brain. PLoS One. 2016;11(1):e0144200.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  69. Pallud J, Mandonnet E, Duffau H, Kujas M, Guillevin R, Galanaud D, et al. Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas. Ann Neurol. 2006;60:380–3.

    Article  PubMed  Google Scholar 

  70. Rees J, Watt H, Jäger HR, Benton C, Tozer D, Tofts P, et al. Volumes and growth rates of untreated adult low-grade gliomas indicate risk of early malignant transformation. Eur J Radiol. 2009;72:54–64.

    Article  PubMed  Google Scholar 

  71. Pallud J, Blonski M, Mandonnet E, Audureau E, Fontaine D, Sanai N, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas. Neuro-Oncol. 2013;15:595–606.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Mandonnet E, Delattre JY, Tanguy ML, Swanson KR, Carpentier AF, Duffau H, et al. Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol. 2003;53:524–8.

    Article  PubMed  Google Scholar 

  73. Mandonnet E, Pallud J, Fontaine D, Taillandier L, Bauchet L, Peruzzi P, et al. Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection. Neurosurg Rev. 2010;33:91–6.

    Article  PubMed  Google Scholar 

  74. Pallud J, Taillandier L, Capelle L, Fontaine D, Peyre M, Ducray F, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade glioma: a plea for systematic measurement of growth rates. Neurosurgery. 2012;71:729–39.

    Article  PubMed  Google Scholar 

  75. Bauman G, Lote K, Larson D, Stalpers L, Leighton C, Fisher B, et al. Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int J Radiat Oncol Biol Phys. 1999;45:923–9.

    Article  CAS  PubMed  Google Scholar 

  76. Chang EF, Smith JS, Chang SM, Lamborn KR, Prados MD, Butowski N, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. J Neurosurg. 2008;109:817–24.

    Article  PubMed  Google Scholar 

  77. Chang EF, Clark A, Jensen RL, Bernstein M, Guha A, Carrabba G, et al. Multiinstitutional validation of the University of California at San Francisco low-grade glioma prognostic scoring system. J Neurosurg. 2009;111:203–10.

    Article  PubMed  Google Scholar 

  78. Jakola AS, Myrmel KS, Kloster R, Torp SH, Lindal S, Unsgård G, Solheim O. Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA. 2012;308:1881–8.

    Article  CAS  PubMed  Google Scholar 

  79. Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol. 2008;26:1338–45.

    Article  PubMed  Google Scholar 

  80. Nita M, Muragaki Y, Maruyama T, Ikuta S, Komori T, Maebayashi K, et al. Proposed therapeutic strategy for adult low-grade glioma based on aggressive tumor resection. Neurosurg Focus. 2015;38(1):E7.

    Article  Google Scholar 

  81. Aghi MK, Nahed BV, Sloan AE, Ryken TC, Kalkanis SN, Olson JJ. The role of surgery in the management of patients with diffuse low gradeglioma: a systematic review and evidence-based clinical practice guideline. J Neuro-Oncol. 2015;125:503–30.

    Article  Google Scholar 

  82. Roelz R, Strohmaier D, Jabbarli R, Kraeutle R, Egger K, Coenen VA, et al. Residual tumor volume as best outcome predictor in low grade glioma – a nine-years near-randomized survey of surgery vs. biopsy. Sci Rep. 2016;6:32286.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Duffau H. Long-term outcomes after supratotal resection of diffuse low-grade gliomas: a consecutive series with 11-year follow-up. Acta Neurochir (Wien). 2016;158:51–8.

    Google Scholar 

  84. van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005;366:985–90.

    Article  PubMed  Google Scholar 

  85. Ryken TC, Parney I, Buatti J, Kalkanis SN, Olson JJ. The role of radiotherapy in the management of patients with diffuse lowgrade glioma: a systematic review and evidence-based clinical practice guideline. J Neuro-Oncol. 2015;125:551–83.

    Article  CAS  Google Scholar 

  86. Ziu M, Kalkanis SN, Gilbert M, Ryken TC, Olson JJ. The role of initial chemotherapy for the treatment of adults with diffuse lowgrade glioma: a systematic review and evidence-based clinical practice guideline. J Neuro-Oncol. 2015;125:585–607.

    Article  CAS  Google Scholar 

  87. Taal W, Bromberg JE, van den Bent MJ. Chemotherapy in glioma. CNS Oncol. 2015;4:179–92.

    Article  CAS  PubMed  Google Scholar 

  88. Le Rhun E, Taillibert S, Chamberlain MC. Current management of adult diffuse infiltrative low grade gliomas. Curr Neurol Neurosci Rep. 2016;16(2):15.

    Article  PubMed  CAS  Google Scholar 

  89. Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade gliomas (EORTC 22033-26033): a randomised, openlabel, phase 3 intergroup study. Lancet Oncol. 2016;17:1521–32.

    Google Scholar 

  90. Duffau H, Taillandier L. New concepts in the management of diffuse low-grade glioma: proposal of a multistage and individualized therapeutic approach. Neuro-Oncol. 2015;17:332–42.

    Article  PubMed  Google Scholar 

  91. Wahl M, Phillips JJ, Molinaro AM, Lin Y, Perry A, Haas-Kogan DA, et al. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. Neuro-Oncol. 2016;29. [Epub ahead of print].

    Google Scholar 

  92. Blonski M, Taillandier L, Herbet G, Maldonado IL, Beauchesne P, Fabbro M, et al. Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life. J Neuro-Oncol. 2012;106:353–66.

    Article  CAS  Google Scholar 

  93. Blonski M, Pallud J, Gozé C, Mandonnet E, Rigau V, Bauchet L, et al. Neoadjuvant chemotherapy may optimize the extent of resection of World Health Organization grade II gliomas: a case series of 17 patients. J Neuro-Oncol. 2013;113:267–75.

    Article  CAS  Google Scholar 

  94. Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med. 2016;374:1344–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Schmidt MH, Berger MS, Lamborn KR, Aldape K, McDermott MW, Prados MD, Chang SM. Repeated operations for infiltrative low-grade gliomas without intervening therapy. J Neurosurg. 2003;98:1165–9.

    Article  PubMed  Google Scholar 

  96. Martino J, Taillandier L, Moritz-Gasser S, Gatignol P, Duffau H. Re-operation is a safe and effective therapeutic strategy in recurrent WHO grade II gliomas within eloquent areas. Acta Neurochir. 2009;151:427–36.

    Article  PubMed  Google Scholar 

  97. Ramakrishna R, Hebb A, Barber J, Rostomily R, Silbergeld D. Outcomes in reoperated low-grade gliomas. Neurosurgery. 2015;77:175–84.

    Article  PubMed  Google Scholar 

  98. van den Bent MJ, Wefel JS, Schiff D, Taphoorn MJ, Jaeckle K, Junck L, et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011;12:583–93.

    Article  PubMed  Google Scholar 

  99. Eisele SC, Wen PY, Lee EQ. Assessment of brain tumor response: RANO and its offspring. Curr Treat Options Oncol. 2016;17:35.

    Article  PubMed  Google Scholar 

  100. McGirt MJ, Chaichana KL, Attenello FJ, Weingart JD, Than K, Burger PC, et al. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery. 2008;63:700–7.

    Article  PubMed  Google Scholar 

  101. Mandonnet E, Duffau H, Bauchet L. A new tool for grade II glioma studies: plotting cumulative time with quality of life versus time to malignant transformation. J Neuro-Oncol. 2012;106:213–5.

    Article  Google Scholar 

  102. Boele FW, Douw L, Reijneveld JC, Robben R, Taphoorn MJ, Aaronson NK, et al. Health-related quality of life in stable, long-term survivors of low-grade glioma. J Clin Oncol. 2015;33:1023–9.

    Article  PubMed  Google Scholar 

  103. Klein M. Treatment options and neurocognitive outcome in patients withdiffuse low-grade glioma. J Neurosurg Sci. 2015;59:383–92.

    CAS  PubMed  Google Scholar 

  104. Fountain DM, Allen D, Joannides AJ, Nandi D, Santarius T, Chari A. Reporting of patient-reported health-related quality of life in adults with diffuse low-grade glioma: a systematic review. Neuro-Oncol. 2016;18(11):1475–86. pii: now107. [Epub ahead of print].

    PubMed  Google Scholar 

  105. Brat DJ, Verhaak RGW, Aldape KD, Yung WKA, Salama SR, Cooper LAD, et al. Cancer Genome Atlas Research Network. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372:2481–98.

    Article  CAS  PubMed  Google Scholar 

  106. Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015;372:2499–508.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Suzuki H, Aoki K, Chiba K, Sato Y, Shiozawa Y, Shiraishi Y, et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet. 2015;47(5):458–68.

    Article  CAS  PubMed  Google Scholar 

  108. Wen PY, Reardon DA. Neuro-oncology in 2015: progress in glioma diagnosis, classification and treatment. Nat Rev Neurol. 2016;12:69–70.

    Article  CAS  PubMed  Google Scholar 

  109. Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell. 2016;164:550–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Rice T, Lachance DH, Molinaro AM, Eckel-Passow JE, Walsh KM, Barnholtz-Sloan J, et al. Understanding inherited genetic risk of adult glioma – a review. Neurooncol Pract. 2016;3:10–6.

    PubMed  Google Scholar 

  111. Duffau H. Stimulation mapping of white matter tracts to study brain functionalconnectivity. Nat Rev Neurol. 2015;11:255–65.

    Article  PubMed  Google Scholar 

  112. De Witt Hamer PC, Robles SG, Zwinderman AH, Duffau H, Berger MS. Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis. J Clin Oncol. 2012;30:2559–65.

    Article  PubMed  Google Scholar 

  113. Bauchet L, Mathieu-Daudé H, Fabbro-Peray P, Rigau V, Fabbro M, Chinot O, et al. Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. Neuro-Oncol. 2010;12:725–35.

    Article  PubMed  PubMed Central  Google Scholar 

  114. Woehrer A, Slavc I, Waldhoer T, Heinzl H, Zielonke N, Czech T, et al. Incidence of atypical teratoid/rhabdoid tumors in children: a population-based study by the Austrian Brain Tumor Registry, 1996–2006. Cancer. 2010;116:5725–32.

    Article  PubMed  Google Scholar 

  115. Terrier LM, Bauchet L, Rigau V, Amelot A, Zouaoui S, Filipiak I, et al. Natural course and prognosis of anaplastic gangliogliomas: a multicenter retrospective study of 43 cases from the French brain tumor database. Neuro-Oncol. pii: now186. [Epub ahead of print].

    Google Scholar 

  116. Bauchet L, Zouaoui S, Darlix A, Rigau V, Mathieu-Daude H, Fabbro-Peray P, et al. Patterns of care for 1,602 patients with newly diagnosed glioblastoma. J Clin Oncol 2015;33. (suppl; abstr e13005).

    Google Scholar 

  117. NCCN Guidelines. Central nervous system cancers. Version 1. 2016. https://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. Accessed 8 August 2016.

  118. National Research Council. Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease. Washington, DC: National Academies Press. https://www.nap.edu/catalog/13284/toward-precision-medicine-building-a-knowledge-network-for-biomedical-research. Accessed 8 August 2016.

  119. Baldock AL, Rockne RC, Boone AD, Neal ML, Hawkins-Daarud A, Corwin DM, et al. From patient-specific mathematical neuro-oncology to precision medicine. Front Oncol. 2013;3:62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  120. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372:793–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  121. NIH. Precision medicine initiative cohort program. https://www.nih.gov/precision-medicine-initiative-cohort-program. Accessed 8 August 2016.

  122. Chen R, Cohen AL, Colman H. Targeted therapeutics in patients with high-grade gliomas: past, present, and future. Curr Treat Options in Oncol. 2016;17:42.

    Article  Google Scholar 

  123. Fujii T, Khawaja MR, DiNardo CD, Atkins JT, Janku F. Targeting isocitrate dehydrogenase (IDH) in cancer. Discov Med. 2016;21:373–80.

    PubMed  Google Scholar 

  124. Binder DC, Davis AA, Wainwright DA. Immunotherapy for cancer in the central nervous system: current and future directions. Oncoimmunology. 2015;5(2):e1082027. eCollection 2016 Feb.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  125. Platten M, Bunse L, Wick W, Bunse T. Concepts in glioma immunotherapy. Cancer Immunol Immunother. 2016;65(10):1269–75. [Epub ahead of print].

    Article  CAS  PubMed  Google Scholar 

  126. Johnson KJ, Hainfellner JA, Lau CC, Scheurer ME, Woehrer A, Wiemels J. Immune factors and viral interactions in brain cancer etiology and outcomes, The 2016 brain tumor epidemiology consortium meeting report. Clin Neuropathol. 2016;35(5):280–6. [Epub ahead of print].

    Article  PubMed  PubMed Central  Google Scholar 

  127. McCarthy BJ, Rankin KM, Aldape K, Bondy ML, Brännström T, Broholm H, et al. Risk factors for oligodendroglial tumors: a pooled international study. Neuro-Oncol. 2011;13:242–50.

    Article  PubMed  Google Scholar 

  128. Gozé C, Bezzina C, Gozé E, Rigau V, Maudelonde T, Bauchet L, et al. 1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth. J Neuro-Oncol. 2012;108:69–75.

    Article  Google Scholar 

  129. Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood LD, Hruban RH, et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science. 2011;333:1453–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  130. Kim YH, Nobusawa S, Mittelbronn M, Paulus W, Brokinkel B, et al. Molecular classification of low-grade diffuse gliomas. Am J Pathol. 2010;177:2708–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  131. Ohgaki H, Kleihues P. Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol. 2011;28:177–83.

    Article  CAS  PubMed  Google Scholar 

  132. Ohgaki H, Kim YH, Steinbach JP. Nervous system tumors associated with familial tumor syndromes. Curr Opin Neurol. 2010;23:583–91.

    Article  CAS  PubMed  Google Scholar 

  133. Kyritsis AP, Bondy ML, Rao JS, Sioka C. Inherited predisposition to glioma. Neuro-Oncol. 2010;12:104–13.

    Article  CAS  PubMed  Google Scholar 

  134. Ron E, Modan B, Boice Jr JD, Alfandary E, Stovall M, Chetrit A, et al. Tumors of the brain and nervous system after radiotherapy in childhood. N Engl J Med. 1988;319:1033–9.

    Article  CAS  PubMed  Google Scholar 

  135. Yonehara S, Brenner AV, Kishikawa M, Inskip PD, Preston DL, Ron E, et al. Clinical and epidemiologic characteristics of first primary tumors of the central nervous system and related organs among atomic bomb survivors in Hiroshima and Nagasaki, 1958–1995. Cancer. 2004;101:1644–54.

    Article  PubMed  Google Scholar 

  136. Hemminki K, Tretli S, Sundquist J, Johannesen TB, Granström C. Familial risks in nervous-system tumours: a histology-specific analysis from Sweden and Norway. Lancet Oncol. 2009;10:481–8.

    Article  PubMed  Google Scholar 

  137. Zhao H, Cai W, Su S, Zhi D, Lu J, Liu S. Allergic conditions reduce the risk of glioma: a meta-analysis based on 128,936 subjects. Tumour Biol. 2014;35:3875–80.

    Article  CAS  PubMed  Google Scholar 

  138. Amirian ES, Zhou R, Wrensch MR, Olson SH, Scheurer ME, Il'yasova D, et al. Approaching a scientific consensus on the association between allergies and glioma risk: a report from the glioma international case-control study. Cancer Epidemiol Biomark Prev. 2016;25:282–90.

    Article  CAS  Google Scholar 

  139. Inskip PD, Hoover RN, Devesa SS. Brain cancer incidence trends in relation to cellular telephone use in the United States. Neuro-Oncol. 2010;12:1147–51.

    Article  PubMed  PubMed Central  Google Scholar 

  140. INTERPHONE Study Group. Brain tumour risk in relation to mobile telephone use: results of the INTERPHONE international case-control study. Int J Epidemiol. 2010;39:675–94.

    Article  Google Scholar 

  141. Deltour I, Auvinen A, Feychting M, Johansen C, Klaeboe L, Sankila R, et al. Mobile phone use and incidence of glioma in the Nordic countries 1979–2008: consistency check. Epidemiology. 2012;23:301–7.

    Article  PubMed  Google Scholar 

  142. Hardell L, Carlberg M, Söderqvist F, Mild KH. Case-control study of the association between malignant brain tumours diagnosed between 2007 and 2009 and mobile and cordless phone use. Int J Oncol. 2013;43:1833–45.

    PubMed  PubMed Central  Google Scholar 

  143. Coureau G, Bouvier G, Lebailly P, Fabbro-Peray P, Gruber A, Leffondre K, et al. Mobile phone use and brain tumours in the CERENAT case-control study. Occup Environ Med. 2014;71:514–22.

    Article  PubMed  Google Scholar 

  144. Turner MC, Benke G, Bowman JD, Figuerola J, Fleming S, Hours M, et al. Occupational exposure to extremely low-frequency magnetic fields and brain tumor risks in the INTEROCC study. Cancer Epidemiol Biomark Prev. 2014;23:1863–72.

    Article  CAS  Google Scholar 

  145. Kim SJ, Ioannides SJ, Elwood JM. Trends in incidence of primary brain cancer in New Zealand, 1995 to 2010. Aust N Z J Public Health. 2015;39:148–52.

    Article  PubMed  Google Scholar 

  146. Sheweita SA, Sheikh BY. Can dietary antioxidants reduce the incidence of brain tumors? Curr Drug Metab. 2011;12:587–93.

    Article  CAS  PubMed  Google Scholar 

  147. Wei Y, Zou D, Cao D, Xie P. Association between processed meat and red meat consumption and risk for glioma: a meta-analysis from 14 articles. Nutrition. 2015;31:45–50.

    Article  PubMed  Google Scholar 

  148. Saneei P, Willett W, Esmaillzadeh A. Red and processed meat consumption and risk of glioma in adults: a systematic review and meta-analysis of observational studies. J Res Med Sci. 2015;20:602–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  149. Zhou S, Wang X, Tan Y, Qiu L, Fang H, Li W. Association between vitamin C intake and glioma risk: evidence from a meta-analysis. Neuroepidemiology. 2015;44:39–44.

    Article  CAS  PubMed  Google Scholar 

  150. Scheurer ME, El-Zein R, Thompson PA, Aldape KD, Levin VA, Gilbert MR, et al. Long-term anti-inflammatory and antihistamine medication use and adult glioma risk. Cancer Epidemiol Biomark Prev. 2008;17:1277–81.

    Article  CAS  Google Scholar 

  151. Ferris J, McCoy L, Neugut AI, Wrensch M, Lai R. HMG CoA reductase inhibitors, NSAIDs and risk of glioma. Int J Cancer. 2012;131:E1031–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  152. Samanic CM, De Roos AJ, Stewart PA, Rajaraman P, Waters MA, Inskip PD. Occupational exposure to pesticides and risk of adult brain tumors. Am J Epidemiol. 2008;167:976–85.

    Article  PubMed  PubMed Central  Google Scholar 

  153. Provost D, Cantagrel A, Lebailly P, Jaffré A, Loyant V, Loiseau H, et al. Brain tumours and exposure to pesticides: a case-control study in southwestern France. Occup Environ Med. 2007;64:509–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  154. Yiin JH, Ruder AM, Stewart PA, Waters MA, Carreón T, Butler MA, et al. The upper midwest health study: a case-control study of pesticide applicators and risk of glioma. Environ Health. 2012;11:39.

    Article  PubMed  PubMed Central  Google Scholar 

  155. Carles C, Bouvier G, Lebailly P, Baldi I. Use of job-exposure matrices to estimate occupational exposure topesticides: a review. J Expo Sci Environ Epidemiol. 2016;27(2):125–40. [Epub ahead of print].

    Article  PubMed  CAS  Google Scholar 

  156. Felini MJ, Olshan AF, Schroeder JC, Carozza SE, Miike R, Rice T, et al. Reproductive factors and hormone use and risk of adult gliomas. Cancer Causes Control. 2009;20:87–96.

    Article  PubMed  Google Scholar 

  157. Krishnamachari B, Il'yasova D, Scheurer ME, Bondy ML, Wrensch M, Davis FG. A pooled multisite analysis of the effects of female reproductive hormones on glioma risk. Cancer Causes Control. 2014;25:1007–13.

    Article  PubMed  PubMed Central  Google Scholar 

  158. Benson VS, Kirichek O, Beral V, Green J. Menopausal hormone therapy and central nervous system tumor risk: large UK prospective study and meta-analysis. Int J Cancer. 2015;136:2369–77.

    Article  CAS  PubMed  Google Scholar 

  159. Benson VS, Pirie K, Green J, Casabonne D, Beral V, Million Women Study Collaborators. Lifestyle factors and primary glioma and meningioma tumours in the million women study cohort. Br J Cancer. 2008;99:185–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  160. Danysh HE, Mitchell LE, Zhang K, Scheurer ME, Lupo PJ. Traffic-related air pollution and the incidence of childhood central nervous system tumors: Texas, 2001–2009. Pediatr Blood Cancer. 2015;62:1572–8.

    Article  CAS  PubMed  Google Scholar 

  161. Poulsen AH, Sørensen M, Andersen ZJ, Ketzel M, Raaschou-Nielsen O. Air pollution from traffic and risk for brain tumors: a nationwide study in Denmark. Cancer Causes Control. 2016;27:473–80.

    Article  PubMed  Google Scholar 

  162. Efird JT. Season of birth and risk for adult onset glioma. Int J Environ Res Public Health. 2010;7:1913–36.

    Article  PubMed  PubMed Central  Google Scholar 

  163. Cobbs CS. Cytomegalovirus and brain tumor: epidemiology, biology and therapeutic aspects. Curr Opin Oncol. 2013;25:682–8.

    Article  PubMed  Google Scholar 

  164. Dey M, Ahmed AU, Lesniak MS. Cytomegalovirus and glioma: putting the cart before the horse. J Neurol Neurosurg Psychiatry. 2015;86:191–9.

    Article  PubMed  Google Scholar 

  165. Schlehofer B, Hettinger I, Ryan P, Blettner M, Preston-Martin S, Little J, et al. Occupational risk factors for low grade and high grade glioma: results from an international case control study of adult brain tumours. Int J Cancer. 2005;113:116–25.

    Article  CAS  PubMed  Google Scholar 

  166. Amirian ES, Armstrong GN, Zhou R, Lau CC, Claus EB, Barnholtz-Sloan JS, et al. The glioma international case-control study: a report from the genetic epidemiology of glioma international consortium. Am J Epidemiol. 2016;183:85–91.

    PubMed  Google Scholar 

  167. Farmer WT, Abrahamsson T, Chierzi S, Lui C, Zaelzer C, Jones EV, et al. Neurons diversify astrocytes in the adult brain through sonic hedgehog signaling. Science. 2016;351:849–54.

    Article  CAS  PubMed  Google Scholar 

  168. Heller JP, Rusakov DA. Morphological plasticity of astroglia: understanding synaptic microenvironment. Glia. 2015;63:2133–51.

    Article  PubMed  PubMed Central  Google Scholar 

  169. Iwadate Y, Fukuda K, Matsutani T, Saeki N. Intrinsic protective mechanisms of the neuron-glia network against glioma invasion. J Clin Neurosci. 2016;26:19–25.

    Article  CAS  PubMed  Google Scholar 

  170. Draganski B, Gaser C, Busch V, Schuierer G, Bogdahn U, May A. Neuroplasticity: changes in grey matter induced by training. Nature. 2004;427:311–2.

    Article  CAS  PubMed  Google Scholar 

  171. Blumenfeld-Katzir T, Pasternak O, Dagan M, Assaf Y. Diffusion MRI of structural brain plasticity induced by a learning and memory task. PLoS One. 2011;6(6):e20678.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  172. Sagi Y, Tavor I, Hofstetter S, Tzur-Moryosef S, Blumenfeld-Katzir T, Assaf Y. Learning in the fast lane: new insights into neuroplasticity. Neuron. 2012;73:1195–203.

    Article  CAS  PubMed  Google Scholar 

  173. Ullian EM, Sapperstein SK, Christopherson KS, Barres BA. Control of synapse number by glia. Science. 2001;291:657–61.

    Article  CAS  PubMed  Google Scholar 

  174. Krencik R, van Asperen JV, Ullian EM. Human astrocytes are distinct contributors to the complexity of synaptic function. Brain Res Bull. 2016;129:66–73. [Epub ahead of print].

    Article  PubMed  CAS  Google Scholar 

  175. Fields RD, Stevens-Graham B. New insights into neuron-glia communication. Science. 2002;298:556–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  176. Fields RD. A new mechanism of nervous system plasticity: activity-dependent myelination. Nat Rev Neurosci. 2015;16:756–67.

    Article  CAS  PubMed  Google Scholar 

  177. Duffau H. Surgery of low-grade gliomas: towards a “functional neurooncology”. Curr Opin Oncol. 2009;21:543–9.

    Article  PubMed  Google Scholar 

  178. Duffau H, Pallud J, Mandonnet E. Evidence for the genesis of WHO grade II glioma in an asymptomatic young adult using repeated MRIs. Acta Neurochir. 2011;153:473–7.

    Article  PubMed  Google Scholar 

  179. Pallud J, Fontaine D, Duffau H, Mandonnet E, Sanai N, Taillandier L, et al. Natural history of incidental World Health Organization grade II gliomas. Ann Neurol. 2010;68:727–33.

    Article  PubMed  Google Scholar 

  180. Cochereau J, Herbet G, Duffau H. Patients with incidental WHO grade II glioma frequently suffer from neuropsychological disturbances. Acta Neurochir. 2016;158:305–12.

    Article  PubMed  Google Scholar 

  181. Lima GL, Duffau H. Is there a risk of seizures in “preventive” awake surgery for incidentaldiffuse low-grade gliomas? J Neurosurg. 2015;122:1397–405.

    Article  PubMed  Google Scholar 

  182. Zhang ZY, Chan AK, Ng HK, Ding XJ, Li YX, Shi ZF, et al. Surgically treated incidentally discovered low-grade gliomas are mostly IDH mutated and 1p19q co-deleted with favorable prognosis. Int J Clin Exp Pathol. 2014;7:8627–36. eCollection 2014.

    PubMed  PubMed Central  Google Scholar 

  183. Gerin C, Pallud J, Grammaticos B, Mandonnet E, Deroulers C, Varlet P, et al. Improving the time-machine: estimating date of birth of grade II gliomas. Cell Prolif. 2012;45:76–90.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Hôpital Gui de Chauliac, Centre Hospitalier Universitaire, 80 Avenue Augustin Fliche, 34 295, Montpellier cedex 5, France

    Luc Bauchet MD, PhD

  2. INSERM U1051, Institut des Neurosciences de Montpellier, Montpellier, France

    Luc Bauchet MD, PhD

  3. French Brain Tumor DataBase, Groupe de Neuro-Oncologie du Languedoc-Roussillon, Registre des Tumeurs de l’Hérault, Institut du Cancer de Montpellier, Montpellier, France

    Luc Bauchet MD, PhD

Authors
  1. Luc Bauchet MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luc Bauchet MD, PhD .

Editor information

Editors and Affiliations

  1. Department of Neurosurgery, Montpellier University Medical Center, INSERM U1051, Institute for Neurosciences of Montpellier, Montpellier, France

    Hugues Duffau

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer-Verlag London Ltd.

About this chapter

Cite this chapter

Bauchet, L. (2017). Epidemiology of Diffuse Low Grade Gliomas. In: Duffau, H. (eds) Diffuse Low-Grade Gliomas in Adults. Springer, Cham. https://doi.org/10.1007/978-3-319-55466-2_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-55466-2_2

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-55464-8

  • Online ISBN: 978-3-319-55466-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation